The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies

References

• Fruman DA, Chiu H, Hopkins BD, et al. The PI3K pathway in human disease. Cell. 2017;170(4):605–635. doi: 10.1016/j.cell.2017.07.029
   PubMed Web of Science ®Google Scholar
• Buzzi F, Xu L, Zuellig RA, et al. Differential effects of protein kinase B/Akt isoforms on glucose homeostasis and islet mass. Mol Cell Biol. 2010;30(3):601–612. doi: 10.1128/MCB.00719-09
   PubMed Web of Science ®Google Scholar
• Hawkins P, Anderson K, Davidson K, et al. Signalling through class I PI3Ks in mammalian cells. Biochem Soc Trans. 2006;34(5):647–662. doi: 10.1042/BST0340647
   PubMedGoogle Scholar
• Walker EH, Perisic O, Ried C, et al. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature. 1999;402(6759):313–320. doi: 10.1038/46319
   PubMed Web of Science ®Google Scholar
• Burke JE, Williams RL. Synergy in activating class I PI3Ks. Trends Biochem Sci. 2015;40(2):88–100. doi: 10.1016/j.tibs.2014.12.003
   PubMed Web of Science ®Google Scholar
• Chen J, Tang H, Hay N, et al. Akt isoforms differentially regulate neutrophil functions. Blood J Am Soc Hematol. 2010;115(21):4237–4246. doi: 10.1182/blood-2009-11-255323
   Google Scholar
• Calamito M, Juntilla MM, Thomas M, et al. Akt1 and Akt2 promote peripheral B-cell maturation and survival. Blood. J Am Society Hematol. 2010;115(20):4043–4050. doi: 10.1182/blood-2009-09-241638
   Google Scholar
• Juntilla MM, Patil VD, Calamito M, et al. AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species. Blood J Am Soc Hematol. 2010;115(20):4030–4038. doi: 10.1182/blood-2009-09-241000
   Google Scholar
• Juntilla MM, Wofford JA, Birnbaum MJ, et al. Akt1 and Akt2 are required for αβ thymocyte survival and differentiation. Proceed Nat Acad Sci. 2007;104(29):12105–12110.
   PubMed Web of Science ®Google Scholar
• Fayard E, Gill J, Paolino M, et al. Deletion of PKBα/Akt1 affects thymic development. PLOS ONE. 2007;2(10):e992. doi: 10.1371/journal.pone.0000992
   PubMed Web of Science ®Google Scholar
• Mao C, Tili EG, Dose M, et al. Unequal contribution of akt isoforms in the double-negative to double-positive thymocyte transition. J Immunol. 2007;178(9):5443–5453. doi: 10.4049/jimmunol.178.9.5443
   PubMed Web of Science ®Google Scholar
• Perry JM, He XC, Sugimura R, et al. Cooperation between both Wnt/β-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev. 2011;25(18):1928–1942. doi: 10.1101/gad.17421911
   PubMed Web of Science ®Google Scholar
• Sandri M, Barberi L, Bijlsma A, et al. Signalling pathways regulating muscle mass in ageing skeletal muscle. The role of the IGF1-akt-mTOR-FoxO pathway. Biogerontology. 2013;14(3):303–323. doi: 10.1007/s10522-013-9432-9
   PubMed Web of Science ®Google Scholar
• Schaeffer EM, Schwartzberg PL. Tec family kinases in lymphocyte signaling and function. Curr Opin Immunol. 2000;12(3):282–288. doi: 10.1016/S0952-7915(00)00088-1
   PubMed Web of Science ®Google Scholar
• Kishimoto H, Hamada K, Saunders M, et al. Physiological functions of pten in mouse tissues. Cell Struct Funct. 2003;28(1):11–21. doi: 10.1247/csf.28.11
   PubMed Web of Science ®Google Scholar
• Brognard J, Sierecki E, Gao T, et al. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of akt signaling by regulating distinct akt isoforms. Mol Cell. 2007;25(6):917–931. doi: 10.1016/j.molcel.2007.02.017
   PubMed Web of Science ®Google Scholar
• Rohrschneider LR, Fuller JF, Wolf I, et al. Structure, function, and biology of SHIP proteins. Genes Dev. 2000;14(5):505–520. doi: 10.1101/gad.14.5.505
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317–330. doi: 10.1038/nri1056
   PubMed Web of Science ®Google Scholar
• Werner M, Hobeika E, Jumaa H. Role of PI3K in the generation and survival of B cells. Immunol Rev. 2010;237(1):55–71. doi: 10.1111/j.1600-065X.2010.00934.x
   PubMedGoogle Scholar
• Cariappa A, Pillai S. Antigen-dependent B-cell development. Curr Opin Immunol. 2002;14(2):241–249. doi: 10.1016/S0952-7915(02)00328-X
   PubMed Web of Science ®Google Scholar
• Hardy RR. B-cell commitment: deciding on the players. Curr Opin Immunol. 2003;15(2):158–165. doi: 10.1016/S0952-7915(03)00012-8
   PubMed Web of Science ®Google Scholar
• Donahue AC, Fruman DA. PI3K signaling controls cell fate at many points in B lymphocyte development and activation. Semin Cell Dev Biol. 2004Apr;15(2):183–97. doi: 10.1016/j.semcdb.2003.12.024
   PubMed Web of Science ®Google Scholar
• Jellusova J, Rickert RC. The PI3K pathway in B cell metabolism. Critical reviews in biochemistry and molecular biology. Crit Rev Biochem Mol Biol. 2016;51(5):359–378. doi: 10.1080/10409238.2016.1215288
   PubMed Web of Science ®Google Scholar
• Corcoran A, Smart F, Cowling R, et al. The interleukin‐7 receptor alpha chain transmits distinct signals for proliferation and differentiation during B lymphopoiesis. Embo J. 1996;15(8):1924–1932. doi: 10.1002/j.1460-2075.1996.tb00543.x
   PubMed Web of Science ®Google Scholar
• Ramadani F, Bolland DJ, Garcon F, et al. The PI3K isoforms p110α and p110δ are essential for pre–B cell receptor signaling and B cell development. Sci Signaling. 2010;3(134):ra60–ra60. doi: 10.1126/scisignal.2001104
   PubMed Web of Science ®Google Scholar
• Dengler HS, Baracho GV, Omori SA, et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol. 2008;9(12):1388–1398. doi: 10.1038/ni.1667
   PubMed Web of Science ®Google Scholar
• Medema RH, Kops GJ, Bos JL, et al. AFX-like forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27 kip1. Nature. 2000;404(6779):782–787. doi: 10.1038/35008115
   PubMed Web of Science ®Google Scholar
• Baracho G, Miletic A, Omori S, et al. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol. 2011;23(2):178–183. doi: 10.1016/j.coi.2011.01.001
   PubMed Web of Science ®Google Scholar
• Medvedovic J, Ebert A, Tagoh H, et al. Pax5: a master regulator of B cell development and leukemogenesis. Adv Immunol. 2011;111:179–206.
   PubMed Web of Science ®Google Scholar
• Abdelrasoul H, Werner M, Setz CS, et al. PI3K induces B-cell development and regulates B cell identity. Sci Rep. 2018;8(1):1–15. doi: 10.1038/s41598-018-19460-5
   PubMedGoogle Scholar
• Szydłowski M, Jabłońska E, Juszczyński P. FOXO1 transcription factor: a critical effector of the PI3K-AKT axis in B-cell development. Int Rev Immunol. 2014;33(2):146–157. doi: 10.3109/08830185.2014.885022
   PubMed Web of Science ®Google Scholar
• Fruman DA, Snapper SB, Yballe CM, et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85α. Science. 1999;283(5400):393–397. doi: 10.1126/science.283.5400.393
   PubMed Web of Science ®Google Scholar
• Suzuki H, Terauchi Y, Fujiwara M, et al. Xid-like immunodeficiency in mice with disruption of the p85α subunit of phosphoinositide 3-kinase. Science. 1999;283(5400):390–392. doi: 10.1126/science.283.5400.390
   PubMed Web of Science ®Google Scholar
• Jou S-T, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110δ in signaling by the B-cell receptor complex. Mol Cell Biol. 2002;22(24):8580–8591. doi: 10.1128/MCB.22.24.8580-8591.2002
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science. 2002;297(5583):1031–1034. doi: 10.1126/science.1073560
   PubMed Web of Science ®Google Scholar
• Clayton E, Bardi G, Bell SE, et al. A crucial role for the p110δ subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med. 2002;196(6):753–763. doi: 10.1084/jem.20020805
   PubMed Web of Science ®Google Scholar
• Suzuki A, Kaisho T, Ohishi M, et al. Critical roles of pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med. 2003;197(5):657–667. doi: 10.1084/jem.20021101
   PubMed Web of Science ®Google Scholar
• Engel P, Zhou L-J, Ord DC, et al. Abnormal B lymphocyte delevopment, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 1995;3(1):39–50. doi: 10.1016/1074-7613(95)90157-4
   PubMed Web of Science ®Google Scholar
• Xu Y, Fairfax K, Light A, et al. CD19 differentially regulates BCR signalling through the recruitment of PI3K. Autoimmunity. 2014;47(7):430–437. doi: 10.3109/08916934.2014.921810
   PubMed Web of Science ®Google Scholar
• Anzelon AN, Wu H, Rickert RC. Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat Immunol. 2003;4(3):287–294. doi: 10.1038/ni892
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Poe JC, Satterthwaite AB, et al. Complementary roles for CD19 and Bruton’s tyrosine kinase in B lymphocyte signal transduction. J Immunol. 2002;168(11):5465–5476. doi: 10.4049/jimmunol.168.11.5465
   PubMed Web of Science ®Google Scholar
• Setz CS, Hug E, Khadour A, et al. PI3K-mediated blimp-1 activation controls B cell selection and homeostasis. Cell Rep. 2018;24(2):391–405. doi: 10.1016/j.celrep.2018.06.035
   PubMed Web of Science ®Google Scholar
• Cornelis R, Hahne S, Taddeo A, et al. Stromal cell-contact dependent PI3K and APRIL induced NF-κB signaling prevent mitochondrial-and ER stress induced death of memory plasma cells. Cell Rep. 2020;32(5):107982. doi: 10.1016/j.celrep.2020.107982
   PubMed Web of Science ®Google Scholar
• Hodson DJ, Turner M. The role of PI3K signalling in the B cell response to antigen. Adv Exp Med Biol. 2009;633:43–53. doi: 10.1007/978-0-387-79311-5_5
   PubMed Web of Science ®Google Scholar
• Aagaard-Tillery KM, Jelinek DF. Phosphatidylinositol 3-kinase activation in normal human B lymphocytes. J Immunol. 1996;156(12):4543–4554. doi: 10.4049/jimmunol.156.12.4543
   PubMed Web of Science ®Google Scholar
• Scharenberg AM, Kinet J-P. PtdIns-3, 4, 5-P3: a regulatory nexus between tyrosine kinases and sustained calcium signals. Cell. 1998;94(1):5–8. doi: 10.1016/S0092-8674(00)81214-3
   PubMed Web of Science ®Google Scholar
• Marshall AJ, Niiro H, Lerner CG, et al. A novel B lymphocyte–associated adaptor protein, Bam32, regulates antigen receptor signaling downstream of phosphatidylinositol 3-kinase. J Exp Med. 2000;191(8):1319–1332. doi: 10.1084/jem.191.8.1319
   PubMed Web of Science ®Google Scholar
• Niiro H, Maeda A, Kurosaki T, et al. The B lymphocyte adaptor molecule of 32 kD (Bam32) regulates B cell antigen receptor signaling and cell survival. J Exp Med. 2002;195(1):143–149. doi: 10.1084/jem.20011524
   PubMed Web of Science ®Google Scholar
• Weber M, Treanor B, Depoil D, et al. Phospholipase C-γ2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen. J Exp Med. 2008;205(4):853–868. doi: 10.1084/jem.20072619
   PubMed Web of Science ®Google Scholar
• Henley T, Kovesdi D, Turner M. B‐cell responses to B‐cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta. Eur J Immunol. 2008;38(12):3543–3548. doi: 10.1002/eji.200838618
   PubMed Web of Science ®Google Scholar
• Ravetch JV, Bolland S. Igg fc receptors. Annu Rev Immunol. 2001;19(1):275–290. doi: 10.1146/annurev.immunol.19.1.275
   PubMedGoogle Scholar
• Kerr WG. Inhibitor and activator: dual functions for SHIP in immunity and cancer. Ann N Y Acad Sci. 2011;1217(1):1. doi: 10.1111/j.1749-6632.2010.05869.x
   PubMedGoogle Scholar
• Chen Z, Wang JH. Signaling control of antibody isotype switching. Adv Immunol. 2019;141:105–164.
   PubMed Web of Science ®Google Scholar
• Stefanová I, Dorfman JR, Germain RN. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature. 2002;420(6914):429–434. doi: 10.1038/nature01146
   PubMed Web of Science ®Google Scholar
• Akashi K, Kondo M, von Freeden-Jeffry U, et al. Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor–deficient mice. Cell. 1997;89(7):1033–1041. doi: 10.1016/S0092-8674(00)80291-3
   PubMed Web of Science ®Google Scholar
• Ciofani M, Zuniga-Pflücker JC. Notch promotes survival of pre–T cells at the β-selection checkpoint by regulating cellular metabolism. Nat Immunol. 2005;6(9):881–888. doi: 10.1038/ni1234
   PubMed Web of Science ®Google Scholar
• Webb LM, Vigorito E, Wymann MP, et al. Cutting edge: T cell development requires the combined activities of the p110γ and p110δ catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol. 2005;175(5):2783–2787. doi: 10.4049/jimmunol.175.5.2783
   PubMed Web of Science ®Google Scholar
• Swat W, Montgrain V, Doggett TA, et al. Essential role of PI3Kδ and PI3Kγ in thymocyte survival. Blood. 2006;107(6):2415–2422. doi: 10.1182/blood-2005-08-3300
   PubMed Web of Science ®Google Scholar
• Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science. 2000;287(5455):1040–1046. doi: 10.1126/science.287.5455.1040
   PubMed Web of Science ®Google Scholar
• Rodríguez-Borlado L, Barber DF, Hernández C, et al. Phosphatidylinositol 3-kinase regulates the CD4/CD8 T cell differentiation ratio. J Immunol. 2003;170(9):4475–4482. doi: 10.4049/jimmunol.170.9.4475
   PubMed Web of Science ®Google Scholar
• Hagenbeek TJ, Naspetti M, Malergue F, et al. The loss of PTEN allows TCR αβ lineage thymocytes to bypass IL-7 and pre-TCR–mediated signaling. J Exp Med. 2004;200(7):883–894. doi: 10.1084/jem.20040495
   PubMed Web of Science ®Google Scholar
• Herman A, Kappler JW, Marrack P, et al. Superantigens: mechanism of T-cell stimulation and role in immune responses. Annu Rev Immunol. 1991;9(1):745–772. doi: 10.1146/annurev.iy.09.040191.003525
   PubMedGoogle Scholar
• Juntilla MM, Koretzky GA. Critical roles of the PI3K/Akt signaling pathway in T cell development. Immunol Lett. 2008;116(2):104–110. doi: 10.1016/j.imlet.2007.12.008
   PubMed Web of Science ®Google Scholar
• Soond DR, Garçon F, Patton DT, et al. Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma. J Immunol. 2012;188(12):5935–5943. doi: 10.4049/jimmunol.1102116
   PubMed Web of Science ®Google Scholar
• Rolf J, Bell SE, Kovesdi D, et al. Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction. J Immunol. 2010;185(7):4042–4052. doi: 10.4049/jimmunol.1001730
   PubMed Web of Science ®Google Scholar
• Nagai S, Kurebayashi Y, Koyasu S. Role of PI3K/Akt and mTOR complexes in Th17 cell differentiation. Ann N Y Acad Sci. 2013;1280(1):30–34. doi: 10.1111/nyas.12059
   PubMedGoogle Scholar
• Freitas AA, Rocha B. Homeostasis of naive T cells: the foxo that fixes. Nat Immunol. 2009;10(2):133–134. doi: 10.1038/ni0209-133
   PubMed Web of Science ®Google Scholar
• Kane LP, Andres PG, Howland KC, et al. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-γ but not TH 2 cytokines. Nat Immunol. 2001;2(1):37–44. doi: 10.1038/83144
   PubMed Web of Science ®Google Scholar
• Fowell DJ, Shinkai K, Liao XC, et al. Impaired NFATc translocation and failure of Th2 development in itk-deficient CD4+ T cells. Immunity. 1999;11(4):399–409. doi: 10.1016/S1074-7613(00)80115-6
   PubMed Web of Science ®Google Scholar
• Schaeffer EM, Yap GS, Lewis CM, et al. Mutation of Tec family kinases alters T helper cell differentiation. Nat Immunol. 2001;2(12):1183–1188. doi: 10.1038/ni734
   PubMed Web of Science ®Google Scholar
• Kim EH, Suresh M. Role of PI3K/Akt signaling in memory CD8 T cell differentiation. Front Immunol. 2013;4:20. doi: 10.3389/fimmu.2013.00020
   PubMed Web of Science ®Google Scholar
• Ward SG, Westwick J, Hall ND, et al. Ligation of CD28 receptor by B7 induces formation of D‐3 phosphoinositides in T lymphocytes independently of T cell receptor/CD3 activation. Eur J Immunol. 1993;23(10):2572–2577. doi: 10.1002/eji.1830231029
   PubMed Web of Science ®Google Scholar
• Costello PS, Gallagher M, Cantrell DA. Sustained and dynamic inositol lipid metabolism inside and outside the immunological synapse. Nat Immunol. 2002;3(11):1082–1089. doi: 10.1038/ni848
   PubMed Web of Science ®Google Scholar
• Harriague J, Bismuth G. Imaging antigen-induced PI3K activation in T cells. Nat Immunol. 2002;3(11):1090–1096. doi: 10.1038/ni847
   PubMed Web of Science ®Google Scholar
• Herrero-Sánchez MC, Rodríguez-Serrano C, Almeida J, et al. Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development. J Hematol Oncol. 2016;9(1):1–14. doi: 10.1186/s13045-016-0343-5
   PubMedGoogle Scholar
• Okada T, Maeda A, Iwamatsu A, et al. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity. 2000;13(6):817–827. doi: 10.1016/S1074-7613(00)00079-0
   PubMed Web of Science ®Google Scholar
• Bruyns E, Marie-Cardine A, Kirchgessner H, et al. T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCR–CD3–ζ complex, recruits intracellular signaling proteins to the plasma membrane. J Exp Med. 1998;188(3):561–575. doi: 10.1084/jem.188.3.561
   PubMed Web of Science ®Google Scholar
• Garçon F, Patton DT, Emery JL, et al. CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer. Blood. 2008;111(3):1464–1471. doi: 10.1182/blood-2007-08-108050
   PubMed Web of Science ®Google Scholar
• Pedros C, Zhang Y, Hu JK, et al. A TRAF-like motif of the inducible costimulator ICOS controls development of germinal center T FH cells via the kinase TBK1. Nat Immunol. 2016;17(7):825–833. doi: 10.1038/ni.3463
   PubMed Web of Science ®Google Scholar
• Reynolds LF, Smyth LA, Norton T, et al. Vav1 transduces T cell receptor signals to the activation of phospholipase C-γ1 via phosphoinositide 3-kinase-dependent and-independent pathways. J Exp Med. 2002;195(9):1103–1114. doi: 10.1084/jem.20011663
   PubMed Web of Science ®Google Scholar
• Liu K-Q, Bunnell SC, Gurniak CB, et al. T cell receptor–initiated calcium release is uncoupled from capacitative calcium entry in itk-deficient T cells. J Exp Med. 1998;187(10):1721–1727. doi: 10.1084/jem.187.10.1721
   PubMed Web of Science ®Google Scholar
• Liao XC, Fournier S, Killeen N, et al. Itk negatively regulates induction of T cell proliferation by CD28 costimulation. J Exp Med. 1997;186(2):221–228. doi: 10.1084/jem.186.2.221
   PubMed Web of Science ®Google Scholar
• Schaeffer EM, Debnath J, Yap G, et al. Requirement for tec kinases rlk and itk in T cell receptor signaling and immunity. Science. 1999;284(5414):638–641. doi: 10.1126/science.284.5414.638
   PubMed Web of Science ®Google Scholar
• Soond DR, Slack E, Garden OA, et al. Does the PI3K pathway promote or antagonize regulatory T cell development and function? Front Immunol. 2012;3:244. doi: 10.3389/fimmu.2012.00244
   PubMed Web of Science ®Google Scholar
• Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol. 2007;7(11):875–888. doi: 10.1038/nri2189
   PubMed Web of Science ®Google Scholar
• Ouyang W, Beckett O, Ma Q, et al. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat Immunol. 2010;11(7):618–627. doi: 10.1038/ni.1884
   PubMed Web of Science ®Google Scholar
• Patton DT, Garden OA, Pearce WP, et al. Cutting edge: the phosphoinositide 3-kinase p110δ is critical for the function of CD4+ CD25+ Foxp3+ regulatory T cells. J Immunol. 2006;177(10):6598–6602. doi: 10.4049/jimmunol.177.10.6598
   PubMed Web of Science ®Google Scholar
• Patterson S, Garcia R, O’Neill A, et al. PHLPP regulates the development, function and molecular signaling pathways of T regulatory cells. Clin Immunol. 2010;135:S6. doi: 10.1016/j.clim.2010.03.025
   Web of Science ®Google Scholar
• Pompura SL, Dominguez‐Villar M. The PI3K/AKT signaling pathway in regulatory T‐cell development, stability, and function. J Leukoc Biol. 2018;103(6):1065–1076. doi: 10.1002/JLB.2MIR0817-349R
   Web of Science ®Google Scholar
• Held W, Roland J, Raulet DH. Allelic exclusion of Ly49-family genes encoding class I MHC-specific receptors on NK cells. Nature. 1995;376(6538):355–358. doi: 10.1038/376355a0
   PubMed Web of Science ®Google Scholar
• Chiesa S, Mingueneau M, Fuseri N, et al. Multiplicity and plasticity of natural killer cell signaling pathways. Blood. 2006;107(6):2364–2372. doi: 10.1182/blood-2005-08-3504
   PubMed Web of Science ®Google Scholar
• Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 2007;7(9):703–714. doi: 10.1038/nri2154
   PubMed Web of Science ®Google Scholar
• Ali AK, Nandagopal N, Lee S-H. IL-15–PI3K–AKT–mTOR: a critical pathway in the life journey of natural killer cells. Front Immunol. 2015;6:355.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6(8):595–601. doi: 10.1038/nri1901
   PubMed Web of Science ®Google Scholar
• Labarrere CA, Woods J, Hardin J, et al. Early prediction of cardiac allograft vasculopathy and heart transplant failure. Am J Transplant. 2011;11(3):528–535. doi: 10.1111/j.1600-6143.2010.03401.x
   PubMed Web of Science ®Google Scholar
• Tassi I, Cella M, Gilfillan S, et al. p110γ and p110δ phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity. 2007;27(2):214–227. doi: 10.1016/j.immuni.2007.07.014
   PubMed Web of Science ®Google Scholar
• Marçais A, Cherfils-Vicini J, Viant C, et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol. 2014;15(8):749–757. doi: 10.1038/ni.2936
   PubMed Web of Science ®Google Scholar
• Awasthi A, Samarakoon A, Dai X, et al. Deletion of PI3K-p85 α gene impairs lineage commitment, terminal maturation, cytokine generation and cytotoxicity of NK cells. Genes Immunity. 2008;9(6):522–535. doi: 10.1038/gene.2008.45
   PubMed Web of Science ®Google Scholar
• Kim N, Saudemont A, Webb L, et al. The p110delta catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood J Am Soc Hematol. 2007;110(9):3202–3208. doi: 10.1182/blood-2007-02-075366
   Google Scholar
• Elbim C, Bailly S, Chollet-Martin S, et al. Differential priming effects of proinflammatory cytokines on human neutrophil oxidative burst in response to bacterial N-formyl peptides. Infect Immun. 1994;62(6):2195–2201. doi: 10.1128/iai.62.6.2195-2201.1994
   PubMed Web of Science ®Google Scholar
• Nandagopal N, Ali AK, Komal AK, et al. The critical role of IL-15–PI3K–mTOR pathway in natural killer cell effector functions. Front Immunol. 2014;5:187. doi: 10.3389/fimmu.2014.00187
   PubMed Web of Science ®Google Scholar
• Loh J, Chu DT, O’Guin AK, et al. Natural killer cells utilize both perforin and gamma interferon to regulate murine cytomegalovirus infection in the spleen and liver. J Virol. 2005;79(1):661–667. doi: 10.1128/JVI.79.1.661-667.2005
   PubMed Web of Science ®Google Scholar
• Jiang K, Zhong B, Gilvary DL, et al. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol. 2000;1(5):419–425. doi: 10.1038/80859
   PubMed Web of Science ®Google Scholar
• Hassani A, Asaadi Tehrani G, Zahmatkesh N, et al. Evaluation the effect of chemotherapy drugs and thiosemicarbazone complexes on the expression of URHC and CASC15 LncRNAs in acute lymphoblastic leukemia cell line. Iran J Blood Cancer. 2023;15(1):1–9. doi: 10.58209/ijbc.15.1.1
   Google Scholar
• Moghimian B, Jafari-Joshaghan A, Shams F, et al. NLR, PLR, and HPR as novel diagnostic biomarkers for acute lymphoblastic leukemia. Iran J Blood Cancer. 2023;15(2):80–87. doi: 10.58209/ijbc.15.2.80
   Google Scholar
• Evangelisti C, Cappellini A, Oliveira M, et al. Phosphatidylinositol 3‐kinase inhibition potentiates glucocorticoid response in B‐cell acute lymphoblastic leukemia. J Cell Physiol. 2018;233(3):1796–1811. doi: 10.1002/jcp.26135
   PubMed Web of Science ®Google Scholar
• Fuka G, Kantner H, Grausenburger R, et al. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. Leukemia. 2012;26(5):927–933. doi: 10.1038/leu.2011.322
   PubMed Web of Science ®Google Scholar
• Tasian SK, Doral MY, Borowitz MJ, et al. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood J Am Soc Hematology. 2012;120(4):833–842. doi: 10.1182/blood-2011-12-389932
   Google Scholar
• Tasian SK, Teachey DT, Li Y, et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2017;129(2):177–187. doi: 10.1182/blood-2016-05-707653
   PubMed Web of Science ®Google Scholar
• Neri LM, Cani A, Martelli A, et al. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia. 2014;28(4):739–748. doi: 10.1038/leu.2013.226.
   PubMed Web of Science ®Google Scholar
• Bashash D, Safaroghli-Azar A, Delshad M, et al. Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: shedding new light on NVP-BKM120 mechanism of action. Int J Biochem Cell Biol. 2016;79:308–317. doi: 10.1016/j.biocel.2016.09.004
   PubMed Web of Science ®Google Scholar
• Safaroghli-Azar A, Bashash D, Sadreazami P, et al. PI3K-δ inhibition using CAL-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells. Anticancer Drugs. 2017;28(4):436–445. doi: 10.1097/CAD.0000000000000477
   PubMed Web of Science ®Google Scholar
• Nucera S, Giustacchini A, Boccalatte F, et al. miRNA-126 orchestrates an oncogenic program in B cell precursor acute lymphoblastic leukemia. Cancer Cell. 2016;29(6):905–921. doi: 10.1016/j.ccell.2016.05.007
   PubMed Web of Science ®Google Scholar
• Teachey DT, Obzut DA, Cooperman J, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood. 2006;107(3):1149–1155. doi: 10.1182/blood-2005-05-1935
   PubMed Web of Science ®Google Scholar
• Simioni C, Cani A, Martelli AM, et al. Activity of the novel mTOR inhibitor torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent akt reactivation. Oncotarget. 2014;5(20):10034. doi: 10.18632/oncotarget.2490
   PubMed Web of Science ®Google Scholar
• Yang X, He G, Gong Y, et al. Mammalian target of rapamycin inhibitor rapamycin enhances anti‐leukemia effect of imatinib on P h+ acute lymphoblastic leukemia cells. Eur J Haematol. 2014;92(2):111–120. doi: 10.1111/ejh.12202
   PubMed Web of Science ®Google Scholar
• Riyahi N, Safaroghli-Azar A, Sheikh-Zeineddini N, et al. Synergistic effects of PI3K and c-myc co-targeting in acute leukemia: shedding new light on resistance to selective PI3K-δ inhibitor CAL-101. Cancer Invest. 2019;37(7):311–324. doi: 10.1080/07357907.2019.1651328
   PubMed Web of Science ®Google Scholar
• Xia T, Zhang J, Zhou C, et al. 20 (S)-ginsenoside Rh2 displays efficacy against T-cell acute lymphoblastic leukemia through the PI3K/Akt/mTOR signal pathway. J Ginseng Res. 2020;44(5):725–737. doi: 10.1016/j.jgr.2019.07.003
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood J Am Soc Hematol. 2009;114(3):647–650. doi: 10.1182/blood-2009-02-206722
   Google Scholar
• You D, Xin J, Volk A, et al. FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells. Cell Rep. 2015;10(12):2055–2068. doi: 10.1016/j.celrep.2015.02.056
   PubMed Web of Science ®Google Scholar
• Schnell SA. Therapeutic targeting of hairy and enhancer of split 1 (HES1) transcriptional programs in T-cell acute lymphoblastic. Leukemia: Columbia University; 2015.
   Google Scholar
• Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Med. 2007;13(10):1203–1210. doi: 10.1038/nm1636
   PubMed Web of Science ®Google Scholar
• Gazi M, Moharram SA, Marhäll A, et al. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL). Cancer Lett. 2017;392:9–16. doi: 10.1016/j.canlet.2017.01.035
   PubMed Web of Science ®Google Scholar
• Shepherd C, Banerjee L, Cheung CW, et al. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia. 2013;27(3):650–660. doi: 10.1038/leu.2012.285
   PubMed Web of Science ®Google Scholar
• Hales EC, Orr SM, Gedman AL, et al. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells. J Biol Chem. 2013;288(31):22836–22848. doi: 10.1074/jbc.M113.451625
   PubMed Web of Science ®Google Scholar
• Ling Z, Fang ZG, Wu JY, et al. The depletion of circ-PRKDC enhances autophagy and apoptosis in T-cell acute lymphoblastic leukemia via microRNA -653-5p/Reelin mediation of the PI3K / AKT / mTOR signaling pathway. Kaohsiung J Med Sci. 2021;37(5):392–401. doi: 10.1002/kjm2.12352
   PubMed Web of Science ®Google Scholar
• Mavrakis KJ, Van Der Meulen J, Wolfe AL, et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nature Genet. 2011;43(7):673–678. doi: 10.1038/ng.858
   PubMed Web of Science ®Google Scholar
• Ye H, Liu X, Lv M, et al. MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res. 2012;40(12):5201–5214. doi: 10.1093/nar/gks175
   PubMed Web of Science ®Google Scholar
• Schult C, Dahlhaus M, Glass A, et al. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Anticancer Res. 2012;32(2):463–474.
   PubMed Web of Science ®Google Scholar
• Chiarini F, Grimaldi C, Ricci F, et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res. 2010;70(20):8097–8107. doi: 10.1158/0008-5472.CAN-10-1814
   PubMed Web of Science ®Google Scholar
• Zhang C, Ryu Y-K, Chen TZ, et al. Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. Leuk Res. 2012;36(3):342–349. doi: 10.1016/j.leukres.2011.10.022
   PubMed Web of Science ®Google Scholar
• Gu L, Zhou C, Liu H, et al. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. J Exp Clin Cancer Res. 2010;29(1):1–9. doi: 10.1186/1756-9966-29-150
   PubMedGoogle Scholar
• Cheson BD, Bennett JM, Grever M, et al. National cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990–4997. doi: 10.1182/blood.V87.12.4990.bloodjournal87124990
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Burger JA. PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL). Curr Top Microbiol Immunol. 2016;393:123–142. doi: 10.1007/82_2015_484
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078–2088. doi: 10.1182/blood-2010-02-271171
   PubMed Web of Science ®Google Scholar
• Longo PG, Laurenti L, Gobessi S, et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2008;111(2):846–855. doi: 10.1182/blood-2007-05-089037
   PubMed Web of Science ®Google Scholar
• Wang LQ, Wong KY, Rosèn A, et al. Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. Oncotarget. 2015;6(42):44422. doi: 10.18632/oncotarget.6251
   PubMedGoogle Scholar
• Palacios F, Abreu C, Prieto D, et al. Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation. Leukemia. 2015;29(1):115–125. doi: 10.1038/leu.2014.158
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood J Am Soc Hematol. 2011;117(2):591–594. doi: 10.1182/blood-2010-03-275305
   Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood J Am Soc Hematol. 2014;123(22):3390–3397. doi: 10.1182/blood-2013-11-535047
   Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603–3612. doi: 10.1182/blood-2011-05-352492
   PubMed Web of Science ®Google Scholar
• Ding W, Shanafelt TD, Lesnick CE, et al. Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. Br J Haematol. 2014;164(1):146. doi: 10.1111/bjh.12564
   PubMed Web of Science ®Google Scholar
• Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446–2455. doi: 10.1182/blood-2018-05-850461
   PubMed Web of Science ®Google Scholar
• Morrison JA, Gulley ML, Pathmanathan R, et al. Differential signaling pathways are activated in the epstein-barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma. Cancer Res. 2004;64(15):5251–5260. doi: 10.1158/0008-5472.CAN-04-0538
   PubMed Web of Science ®Google Scholar
• Márk Á, Hajdu M, Váradi Z, et al. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease–a combined tissue microarray, in vitro and in vivo study. BMC Cancer. 2013;13(1):1–12. doi: 10.1186/1471-2407-13-250
   PubMedGoogle Scholar
• Nagel S, Scherr M, Quentmeier H, et al. HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3. Leukemia. 2005;19(5):841–846. doi: 10.1038/sj.leu.2403716
   PubMed Web of Science ®Google Scholar
• Georgakis GV, Li Y, Rassidakis GZ, et al. Inhibition of the phosphatidylinositol‐3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in hodgkin lymphoma. Br J Haematol. 2006;132(4):503–511. doi: 10.1111/j.1365-2141.2005.05881.x
   PubMed Web of Science ®Google Scholar
• Dutton A, Reynolds GM, Dawson CW, et al. Constitutive activation of phosphatidyl‐inositide 3 kinase contributes to the survival of Hodgkin’s lymphoma cells through a mechanism involving akt kinase and mTOR. J Pathol. 2005;205(4):498–506. doi: 10.1002/path.1725
   PubMed Web of Science ®Google Scholar
• Xie L, Ushmorov A, Leithäuser F, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood J Am Soc Hematology. 2012;119(15):3503–3511. doi: 10.1182/blood-2011-09-381905
   Google Scholar
• de Yébenes VG, Bartolomé‐Izquierdo N, Ramiro AR. Regulation of B‐cell development and function by micro RNA s. Immunol Rev. 2013;253(1):25–39. doi: 10.1111/imr.12046
   PubMedGoogle Scholar
• Gibcus JH, Tan LP, Harms G, et al. Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia. 2009;11(2):167–IN9. doi: 10.1593/neo.08980
   PubMed Web of Science ®Google Scholar
• Yuan Y, Niu F, Nolte IM, et al. MicroRNA high throughput loss-of-function screening reveals an oncogenic role for miR-21-5p in Hodgkin lymphoma. Cell Physiol Biochem. 2018;49(1):144–159. doi: 10.1159/000492850
   PubMedGoogle Scholar
• Flinn IW, Horwitz SM, Patel M, et al. Clinical safety and activity in a Phase 1 trial of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ, γ, in patients with advanced hematologic malignancies. Blood. 2012 Nov 16;120(21):3663. doi: 10.1182/blood.V120.21.3663.3663
   Web of Science ®Google Scholar
• Meadows SA, Vega F, Kashishian A, et al. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of hodgkin lymphoma. Blood J Am Soc Hematol. 2012;119(8):1897–1900. doi: 10.1182/blood-2011-10-386763
   Google Scholar
• Guidetti A, Viviani S, Marchianò A, et al. Dual targeted therapy with the AKT inhibitor perifosine and the multikinase inhibitor sorafenib in patients with relapsed/refractory lymphomas: final results of a phase II trial. Blood. 2012 Nov 16;120(21):3679. doi: 10.1182/blood.V120.21.3679.3679
   Web of Science ®Google Scholar
• Johnston PB, Pinter-Brown L, Rogerio J, et al. Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study. Blood. 2012 Nov 16;120(21):2740. doi: 10.1182/blood.V120.21.2740.2740
   Web of Science ®Google Scholar
• Valla K, Flowers CR, Koff JL. Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opin Investig Drugs. 2018;27(6):513–522. doi: 10.1080/13543784.2018.1482273
   PubMed Web of Science ®Google Scholar
• Zuo W, Zhu Y, Liu Z, et al. BRD4 inhibition sensitizes aggressive non-hodgkin lymphomas to PI3Kδ inhibitors by suppressing PI3K reactivation and c-MYC expression. Am J Cancer Res. 2021;11(1):215.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Vick E, Huber B, et al. Aurora plus PI3K inhibition abrogates PD-L1 induction in peripheral T-cell non-hodgkin lymphoma. Washington (DC): American Society of Hematology; 2015.
   Google Scholar
• Go H, Jang J-Y, Kim P-J, et al. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget. 2015;6(17):15035. doi: 10.18632/oncotarget.3729
   PubMedGoogle Scholar
• Bedewy AM, Elmaghraby SM, Shehata AA, et al. Prognostic value of miRNA-155 expression in B-cell non-hodgkin lymphoma. Turkish Journal Of Hematology. 2017;34(3):207. doi: 10.4274/tjh.2016.0286
   PubMed Web of Science ®Google Scholar
• Qian D, Chen K, Deng H, et al. MicroRNA-374b suppresses proliferation and promotes apoptosis in T-cell lymphoblastic lymphoma by repressing AKT1 and wnt-16. Clin Cancer Res. 2015;21(21):4881–4891. doi: 10.1158/1078-0432.CCR-14-2947
   PubMed Web of Science ®Google Scholar
• Miller BW, Przepiorka D, de Claro RA, et al. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin Cancer Res. 2015;21(7):1525–1529. doi: 10.1158/1078-0432.CCR-14-2522
   PubMed Web of Science ®Google Scholar
• Barrientos JC. Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. Onco Targets Ther. 2016;9:2945. doi: 10.2147/OTT.S102573
   PubMed Web of Science ®Google Scholar
• Brown JR, Davids MS, Rodon J, et al. Update on the safety and efficacy of the pan class I PI3K inhibitor SAR245408 (XL147) in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma patients. Washington (DC): American Society of Hematology; 2013.
   Google Scholar
• Patnaik A, Ramanathan RK, Appleman LJ, et al. Phase I study of intravenous PI3K inhibitor bay 80-6946: Preliminary activity in patients with relapsed non-Hodgkin lymphoma (NHL) treated in an MTD expansion cohort. Blood. 2012 Nov 16;120(21):3704. doi: 10.1182/blood.V120.21.3704.3704
   Web of Science ®Google Scholar
• Krause G, Hassenrück F, Hallek M. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Design Develop Therapy. 2018;12:2577. doi: 10.2147/DDDT.S142406
   PubMed Web of Science ®Google Scholar
• Flinn IW, Patel M, Oki Y, et al. Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study. Am J Hematol. 2018;93(11):1311–1317. doi: 10.1002/ajh.25228
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139. doi: 10.1056/NEJMoa040938
   PubMed Web of Science ®Google Scholar
• Phillips TJ, Corradini P, Gurion R, et al. Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lymphoma (CITADEL-204). Blood. 2020;136(Supplement 1):27–28. doi: 10.1182/blood-2020-134451
   Google Scholar
• Hu J, Wang J, Dai X, et al. Abstract 5454: amdizalisib (HMPL-689), a highly selective PI3Kδ inhibitor, exhibits potent anti-tumor activity in pre-clinical B-cell lymphoma models. Cancer Res. 2022;82(12_Supplement):5454–5454. doi: 10.1158/1538-7445.AM2022-5454
   Google Scholar
• Wang T, Sun X, Qiu L, et al. The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: a phase II, single-arm, open-label clinical trial. Clin Cancer Res. 2023;29(8):1440–1449. doi: 10.1158/1078-0432.CCR-22-2939
   PubMed Web of Science ®Google Scholar
• Sohani M, Rastgar A, Kheyrandish S. Harnessing the power of MAGE proteins in cancer immunotherapy for multiple myeloma. Iran J Blood Cancer. 2023;15(5):304–327.
   Google Scholar
• Ramakrishnan V, Kumar S. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise. Leukemia Lymphoma. 2018;59(11):2524–2534. doi: 10.1080/10428194.2017.1421760
   PubMed Web of Science ®Google Scholar
• J-H H, Shi Y, Frost P, et al. Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS-dependent and, separately, through p85-dependent pathways. Oncogene. 2004;23(19):3368–3375. doi: 10.1038/sj.onc.1207459
   PubMed Web of Science ®Google Scholar
• Menu E, Kooijman R, Van Valckenborgh E, et al. Specific roles for the PI3K and the MEK–ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer. 2004;90(5):1076–1083. doi: 10.1038/sj.bjc.6601613
   PubMed Web of Science ®Google Scholar
• Baumann P, Schneider L, Mandl-Weber S, et al. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012;23(1):131–138. doi: 10.1097/CAD.0b013e32834c8683
   PubMed Web of Science ®Google Scholar
• Safaroghli-Azar A, Bashash D, Kazemi A, et al. Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: shedding new light on the mechanisms involved in BKM120 resistance. Eur J Pharmacol. 2019;842:89–98. doi: 10.1016/j.ejphar.2018.10.036
   PubMed Web of Science ®Google Scholar
• Ramakrishnan V, Gomez M, Prasad V, et al. Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma. Oncotarget. 2016;7(35):56253. doi: 10.18632/oncotarget.11028
   PubMedGoogle Scholar
• Wang L, Lin N, Li Y. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma. Oncol Rep. 2019;41(3):1678–1690. doi: 10.3892/or.2019.6968
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chang H, Chen G. Effects of microRNA‑20a on the proliferation, migration and apoptosis of multiple myeloma via the PTEN/PI3K/AKT signaling pathway. Oncol Lett. 2018;15(6):10001–10007. doi: 10.3892/ol.2018.8555
   PubMed Web of Science ®Google Scholar
• Yang N, Chen J, Zhang H, et al. LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma. Cell Death Dis. 2017;8(8):e2975–e2975. doi: 10.1038/cddis.2017.358
   PubMed Web of Science ®Google Scholar
• Xu H, Li J, Zhou Z. NEAT1 promotes cell proliferation in multiple myeloma by activating PI3K/AKT pathway. Eur Rev Med Pharmacol Sci. 2018;22(19):6403–6411. doi: 10.26355/eurrev_201810_16053
   PubMed Web of Science ®Google Scholar
• Munugalavadla V, Mariathasan S, Slaga D, et al. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Oncogene. 2014;33(3):316–325. doi: 10.1038/onc.2012.594
   PubMed Web of Science ®Google Scholar
• Baumann P, Mandl-Weber S, Oduncu F, et al. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res. 2009;315(3):485–497. doi: 10.1016/j.yexcr.2008.11.007
   PubMed Web of Science ®Google Scholar
• Mimura N, Hideshima T, Shimomura T, et al. Selective and potent akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res. 2014;74(16):4458–4469. doi: 10.1158/0008-5472.CAN-13-3652
   PubMed Web of Science ®Google Scholar
• Bressanin D, Evangelisti C, Ricci F, et al. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. Oncotarget. 2012;3(8):811. doi: 10.18632/oncotarget.579
   PubMedGoogle Scholar
• Hall CP, Reynolds CP, Kang MH. Modulation of glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia by increasing BIM expression with the PI3K/mTOR inhibitor BEZ235. Clin Cancer Res. 2016;22(3):621–632. doi: 10.1158/1078-0432.CCR-15-0114
   PubMed Web of Science ®Google Scholar
• Zhelev Z, Ivanova D, Bakalova R, et al. Synergistic cytotoxicity of melatonin and new-generation anticancer drugs against leukemia lymphocytes but not normal lymphocytes. Anticancer Res. 2017;37(1):149–159. doi: 10.21873/anticanres.11300
   PubMed Web of Science ®Google Scholar
• Pikman Y, Alexe G, Roti G, et al. Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2017;23(4):1012–1024. doi: 10.1158/1078-0432.CCR-15-2869
   PubMed Web of Science ®Google Scholar
• Chen Y, Peubez C, Smith V, et al. CUDC -907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL. J Cellular Mol Medi. 2019;23(1):340–348. doi: 10.1111/jcmm.13935
   PubMed Web of Science ®Google Scholar
• Gaudio E, Kwee I, Spriano F, et al. The phosphatidylinositol-3-kinase (PI3K) inhibitor (i) copanlisib is active in preclinical models of B-cell lymphomas as single agent and in combination with conventional and targeted agents including venetoclax and palbociclib. Cancer Research. 2017;77(13_Supplement):154–154. doi: 10.1158/1538-7445.AM2017-154
   Google Scholar
• Ito S, Oyake T, Murai K, et al. Deguelin Induces Cell Growth Arrest and Cell Death by Destabilizing Phosphorylated STAT3 and Survivin in Adult T-Cell Leukemia Cells. Blood. 2009;114(22):4784. doi: 10.1182/blood.V114.22.4784.4784
   PubMedGoogle Scholar
• Maharaj KK, Powers JJ, Pabon-Saldana M, et al. Modulation of T cell compartment in a preclinical CLL murine model by a selective PI3K delta inhibitor, TGR-1202. Washington (DC): American Society of Hematology; 2016.
   Google Scholar
• Rebolleda N, Losada-Fernandez I, Perez-Chacon G, et al. Synergistic activity of deguelin and fludarabine in cells from chronic lymphocytic leukemia patients and in the New Zealand black murine model. PLOS ONE. 2016;11(4):e0154159. doi: 10.1371/journal.pone.0154159
   PubMed Web of Science ®Google Scholar
• Xu W, Kim J-W, Jung WJ, et al. Crizotinib in combination with everolimus synergistically inhibits proliferation of anaplastic lymphoma kinase‒positive anaplastic large cell lymphoma. Cancer Res Treat. 2018;50(2):599. doi: 10.4143/crt.2016.357
   PubMed Web of Science ®Google Scholar
• Faia K, White K, Murphy E, et al. The phosphoinositide-3 kinase (PI3K)-δ, γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies. PLOS ONE. 2018;13(8):e0200725. doi: 10.1371/journal.pone.0200725
   PubMed Web of Science ®Google Scholar
• Spriano F, Tarantelli C, Gaudio E, et al. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP‐319 in pre‐clinical models of aggressive lymphomas. Br J Haematol. 2019;187(5):595–601. doi: 10.1111/bjh.16118
   PubMed Web of Science ®Google Scholar
• Mazan-Mamczarz K, Peroutka RJ, Steinhardt JJ, et al. Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma. Cell Commun Signaling. 2015;13(1):1–17. doi: 10.1186/s12964-015-0091-0
   PubMedGoogle Scholar
• Scuoppo C, Wang J, Persaud M, et al. Repurposing dasatinib for diffuse large B cell lymphoma. In: Proceed Nat Acad Sci. 2019;116(34):16981–16986.
   PubMed Web of Science ®Google Scholar
• Larson S, Peng MY, Mead M, et al. Phospho-S6 levels correlate with response to Copanlisib (BAY 80-6946) in multiple myeloma. Cancer Research. 2017 Jul 1;77(13_Supplement):136–136. doi: 10.1158/1538-7445.AM2017-136
   Google Scholar
• Yang C, Huang X, Liu H, et al. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242. Oncotarget. 2017;8(24):39185. doi: 10.18632/oncotarget.16642
   PubMedGoogle Scholar
• Han K, Xu X, Chen G, et al. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization. J Hematol Oncol. 2014;7(1):1–13. doi: 10.1186/1756-8722-7-9
   PubMedGoogle Scholar
• Yu W, Chen Y, Xiang R, et al. Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance. Leukemia Lymphoma. 2017;58(2):428–437. doi: 10.1080/10428194.2016.1190968
   PubMed Web of Science ®Google Scholar
• Hanker AB, Kaklamani V, Arteaga CL. Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in solid tumors. Cancer Discov. 2019;9(4):482–491. doi: 10.1158/2159-8290.CD-18-1175
   PubMed Web of Science ®Google Scholar
• von Keudell G, Moskowitz AJ. The role of PI3K inhibition in lymphoid malignancies. Curr Hematol Malignancy Rep. 2019;14(5):405–413. doi: 10.1007/s11899-019-00540-w
   PubMed Web of Science ®Google Scholar
• Hanlon A, Brander DM. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors. Hematol 2014 Am Soc Hematol Educ Program Book. 2020;2020(1):346–356. doi: 10.1182/hematology.2020000119
   PubMedGoogle Scholar
• Nunnery S, Mayer I. Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol. 2019;30:x21–x26. doi: 10.1093/annonc/mdz440
   Web of Science ®Google Scholar
• Esposito A, Viale G, Curigliano G. Safety, tolerability, and management of toxic effects of phosphatidylinositol 3-kinase inhibitor treatment in patients with cancer: a review. JAMA Oncol. 2019;5(9):1347–1354. doi: 10.1001/jamaoncol.2019.0034
   PubMed Web of Science ®Google Scholar
• Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nature reviews drug discovery. Nat Rev Drug Discov. 2014;13(2):140–156. doi: 10.1038/nrd4204
   PubMed Web of Science ®Google Scholar
• De Santis MC, Gulluni F, Campa CC, et al. Targeting PI3K signaling in cancer: challenges and advances. Biochim Biophys Acta (BBA)- Rev Cancer. 2019;1871(2):361–366. doi: 10.1016/j.bbcan.2019.03.003
   PubMed Web of Science ®Google Scholar